Andes Virus: No Vaccine or Treatment Available

A Maritime Cluster Reigniting Global Health Vigilance

The report from the WHO concerns an outbreak confined to the MV Hondius ship, with a provisional toll of 8 reported cases, including 6 confirmed and 3 deaths. The hypothesis of exposure to the Andes virus guides the epidemiological investigation, as this South American hantavirus has the specific possibility of human-to-human transmission, unlike most other strains that are primarily transmitted via contact with the excrement, urine, or saliva of infected rodents.

The ECDC highlights an important operational point for risk management: the incubation period can range from 2 to 8 weeks. This duration complicates contact tracing and the rapid assessment of potential spread, two parameters that health authorities usually consider in their assessment of the risk of expansion.

From a strictly economic and financial perspective, this event occurs in a market context where exogenous factors already affect risk perception, as illustrated by recent fluctuations in oil prices related to geopolitical tensions in the Middle East.

Limited Coverage for Supportive Care

As it stands, there is no specific antiviral treatment or approved vaccine against the Andes virus. The WHO also confirms the lack of a widely available treatment or vaccine for all hantavirus infections.

Therefore, management relies exclusively on supportive care, with intensive care required for severe pulmonary forms, which are the most dreaded clinical manifestation of the infection. This reliance on extensive hospital capacity represents a structural vulnerability: in the event of an outbreak, the strain would directly impact critical care services, without targeted therapeutic options to reduce the severity or duration of the disease.

Vaccine Players Identified: A Limited Industrial Landscape

The cluster brings attention to the few publicly listed players focused on the hantavirus segment. GC Biopharma, based in South Korea, has historically marketed Hantavax, an inactivated vaccine targeting the Hantaan and Seoul viruses, which are responsible for hemorrhagic fever with renal syndrome. However, this product does not cover the Andes virus or the associated pulmonary syndrome, and its long-term protection is considered limited.

In the United States, Moderna is conducting very early-stage preclinical work on hantavirus countermeasures, in partnership with the US Army Medical Research Institute of Infectious Diseases and Korea University. No approved vaccine exists at this stage, and no solid public clinical timeline has been communicated.

Other avenues remain at the academic stage: the Korea University Vaccine Innovation Center is developing an mRNA candidate with Korean public support, in collaboration with EyeGene and Medici Bio, while the University of Bath and its spin-out Ensilitech are working on an experimental vaccine. These programs remain far from commercialization, objectively limiting the available industrial depth should the situation evolve.